Literature DB >> 17349866

Involvement of neuropeptide systems in schizophrenia: human studies.

Ricardo Cáceda1, Becky Kinkead, Charles B Nemeroff.   

Abstract

Neuropeptides are heterogeneously distributed throughout the digestive, circulatory, and nervous systems and serve as neurotransmitters, neuromodulators, and hormones. Neuropeptides are phylogenetically conserved and have been demonstrated to regulate numerous behaviors. They have been hypothesized to be pathologically involved in several psychiatric disorders, including schizophrenia. On the basis of preclinical data, numerous studies have sought to examine the role of neuropeptide systems in schizophrenia. This chapter reviews the clinical data, linking alterations in neuropeptide systems to the etiology, pathophysiology, and treatment of schizophrenia. Data for the following neuropeptide systems are included: arginine-vasopressin, cholecystokinin (CCK), corticotropin-releasing factor (CRF), interleukins, neuregulin 1 (NRG1), neurotensin (NT), neuropeptide Y (NPY), opioids, secretin, somatostatin, tachykinins, thyrotropin-releasing hormone (TRH), and vasoactive intestinal peptide (VIP). Data from cerebrospinal fluid (CSF), postmortem and genetic studies, as well as clinical trials are described. Despite the inherent difficulties associated with human studies (including small sample size, variable duration of illness, medication status, the presence of comorbid psychiatric disorders, and diagnostic heterogeneity), several findings are noteworthy. Postmortem studies support disease-related alterations in several neuropeptide systems in the frontal and temporal cortices. The strongest genetic evidence supporting a role for neuropeptides in schizophrenia are those studies linking polymorphisms in NRG1 and the CCKA receptor with schizophrenia. Finally, the only compounds that act directly on neuropeptide systems that have demonstrated therapeutic efficacy in schizophrenia are neurokinin receptor antagonists. Clearly, additional investigation into the role of neuropeptide systems in the etiology, pathophysiology, and treatment of schizophrenia is warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349866     DOI: 10.1016/S0074-7742(06)78011-4

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  5 in total

1.  Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia.

Authors:  Agnieszka Markiewicz-Gospodarek; Renata Markiewicz; Beata Dobrowolska; Ryszard Maciejewski; Bartosz Łoza
Journal:  Brain Sci       Date:  2022-06-11

Review 2.  Neurodevelopmental disease mechanisms, primary cilia, and endosomes converge on the BLOC-1 and BORC complexes.

Authors:  Cortnie Hartwig; William J Monis; Xun Chen; Dion K Dickman; Gregory J Pazour; Victor Faundez
Journal:  Dev Neurobiol       Date:  2017-10-13       Impact factor: 3.964

3.  Structural synaptic elements are differentially regulated in superior temporal cortex of schizophrenia patients.

Authors:  Andrea Schmitt; Fernando Leonardi-Essmann; Pascal F Durrenberger; Sven P Wichert; Rainer Spanagel; Thomas Arzberger; Hans Kretzschmar; Mathias Zink; Mario Herrera-Marschitz; Richard Reynolds; Moritz J Rossner; Peter Falkai; Peter J Gebicke-Haerter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-23       Impact factor: 5.270

4.  The origin of neocortical nitric oxide synthase-expressing inhibitory neurons.

Authors:  Xavier H Jaglin; Jens Hjerling-Leffler; Gord Fishell; Renata Batista-Brito
Journal:  Front Neural Circuits       Date:  2012-07-09       Impact factor: 3.492

Review 5.  Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A "Dimmer-Switch" Hypothesis.

Authors:  Santiago J Ballaz; Michel Bourin
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.